For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251229:nRSc0406Na&default-theme=true
RNS Number : 0406N Adalan Ventures PLC 29 December 2025
Not for release or distribution, directly or indirectly, within, into or in
the United States or to or for the account or benefit of persons in the United
States, Australia, Canada, Japan or any other jurisdiction where such offer or
sale would violate the relevant securities laws of such jurisdiction.
For Immediate Release
29(th) December 2025
Adalan Ventures Plc
("Adalan" or the "Company")
Unaudited Interim results for 6 months ended 30 June 2024
Adalan Ventures plc (the 'Company' or 'Adalan'), announces its unaudited
interim results for the 6 month period ended 30 June 2024.
The results follow at the bottom of this announcement.
Enquiries:
Adalan Ventures Plc
Siro Cicconi
Tel: +44 (0) 73 9377 9849
This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.
Adalan Ventures plc
Interim Condensed Consolidated Statement of profit or loss and Other
Comprehensive Income for the six months ended 30 June
Notes Six months ended 30 June 2024 Six months ended 30
Unaudited June 2023
£ Unaudited
£
Staff Costs (114,464) -
Operating expenses (93,711) (10,000)
Loss before income tax (208,175) (10,000)
-
Income tax expense
Net loss (208,175) (10,000)
Net other comprehensive income that may be reclassified to profit or loss
Foreign exchange differences arising on translation into presentation currency - -
Total comprehensive loss (208,175) (10,000)
Adalan Ventures plc
Interim Condensed Consolidated Statement of financial position as at
Notes 30 June 31 December 2023
2024 Audited
Unaudited £
£
Assets:
Cash and cash equivalents 6,664 58,116
Total Assets 6,664 58,116
Liabilities
Other liabilities (789,670) (633,947)
Total liabilities (789,670) (633,947)
Net Assets (783,006) (574,831)
Equity
Capital and reserves:
Share capital 8 513,475 513,475
Deferred Share Capital 4,157,775 4,157,775
Share Premium 8 6,910,128 6,910,128
Share options Reserve 119,640 119,640
Accumulated deficit (12,484,024) (12,275,849)
Total equity (783,006) (574,831)
Total liabilities and equity 6,664 58,116
Interim Condensed Statement of changes in shareholders' equity (Unaudited)
for the six months ended 30 June 2024 (unaudited)
Share capital Share Premium Accumulated Total
Equity
£ £ Deficit
£
£
Deferred Share Capital Share options Reserve
£ £
Balance as at 1 January 2024 513,475
4,157,775 6,910,128 119,640 (12,275,849) (574,831)
Issue of ordinary shares - - - - - -
Comprehensive loss for the period - - - - (208,175) (208,175)
Share-based payments - - - - - -
Balance as at 30 June 2024 513,475 6,910,128 (12,484,024) (783,006)
4,157,775 119,640
Interim Condensed Consolidated Statement of Cash Flows
For the six months ended 30 June
Six months ended 30 Six months
June 2024 ended 30
Unaudited June 2023
£ Unaudited
£
Cash flows from operating activities
Loss for the period (208,175) (10,000)
Cash from operations (208,175) (10,000)
Net (increase)/decrease in operating assets
Change in receivables -
Change in payables 155,723 4,000
Net change in working capital 155,723 4,000
Net cash flows from operating activities (52,452)) (6,000)
Net change in cash and cash equivalents (52,452) (6,000)
58,116 35,468
Cash and cash equivalents at the beginning of the year
Effects of Foreign exchange 1,000 -
Cash and cash equivalents at the end of the period 6,664 29,468
2. Basis of preparation
The condensed consolidated interim financial statements have been prepared
using accounting policies consistent with International Financial Reporting
Standards and in accordance with International Accounting Standard 34 Interim
Financial Reporting. The condensed interim financial statements should be read
in conjunction with the annual financial statements for the year ended 31
December 2022, which have been prepared in accordance with International
Financial Reporting Standards (IFRS).
The condensed consolidated interim financial statements set out above do not
constitute statutory accounts within the meaning of the Companies Act 2006.
They have been prepared on a going concern basis in accordance with the
recognition and measurement criteria of International Financial Reporting
Standards (IFRS). Statutory financial statements for the year ended 31
December 2023 were approved by the Board of Directors on 11 February 2025 and
delivered to the Registrar of Companies. The report of the auditors on those
financial statements was unqualified.
The condensed consolidated interim financial statements of the Company have
not been audited or reviewed by the Company's auditor, RPG Crouch Chapman LLP.
Going concern
The Financial Statements have been prepared on a going concern basis. The
Directors consider that the Company requires additional funding in order to
deliver on its plan to find and acquire an operating business and undertake a
reverse take over. The Directors are of the view that its current cash
reserves along with any funding that it will seek to raise would provide
sufficient funds to undertake its operating activities for the foreseeable
future. Should the company be unsuccessful in raising additional capital then
there is a significant risk that it has the ability to continue as a going
concern. The company has currently reduced its cash expenditure to a
minimum.
Please refer to the going concern note in the annual report for the year ended
31 December 2023 for further information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR DKLFLELLLFBL
Copyright 2019 Regulatory News Service, all rights reserved